Insulet | PODD - Gross Profit On Sales

Stock Price
242.72
Daily Change
1.90 0.79%
Monthly
-14.20%
Yearly
-13.49%
Q1 Forecast
234.50

Insulet reported $510.1M in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
Abbott USD 6.54B 625M Dec/2025
Align Technology USD 683.59M 44.39M Dec/2025
AtriCure USD 101.33M 150K Sep/2025
Avanos Medical USD 86M 6.1M Sep/2025
Baxter International USD 577M 373M Dec/2025
Becton, Dickinson and Co. USD 2.41B 1.72B Dec/2025
Boston Scientific USD 3.68B 136M Dec/2025
Cardinal Health USD 2.4B 78M Dec/2025
Cooper Companies USD 650.8M 62.6M Sep/2025
Dexcom USD 792.7M 61.3M Dec/2025
Edwards Lifesciences USD 1.23B 18.7M Dec/2025
Eli Lilly USD 14.59B 1.48B Sep/2025
Globus Medical USD 486.67M 725.06M Sep/2025
ICU Medical USD 200.88M 7.18M Sep/2025
Inogen USD 41.34M 1.39M Sep/2024
Insulet USD 510.1M 57.9M Sep/2025
Integra LifeSciences USD 206.99M 2.34M Sep/2025
J&J USD 16.6B 118M Dec/2025
Masimo USD 230.6M 2.7M Sep/2025
Medtronic USD 5.44B 123M Sep/2025
Merit Medical Systems USD 184.49M 12.47M Jun/2025
Roche Holding CHF 22.09B 10.04B Dec/2025
Solventum Corp USD 1.14B 40M Sep/2025
Stryker USD 4.49B 633M Dec/2025
Tandem Diabetes Care USD 134.29M 8.44M Sep/2025
Teleflex USD 451.64M 20.56M Sep/2025
West Pharmaceutical Services USD 303.9M 9.6M Dec/2025
Zimmer Biomet Holdings USD 1.27B 8.1M Dec/2025